About
NeuroQuest has developed NeuroScreen™, a novel blood-based diagnostic test for Alzheimer's disease (AD). The technology is based on the specific response of the immune system to a amyloid-beta accumulation. The company's propriety technology is based on the award-winning research of Professor Michal Schwartz of the Weizmann Institute of Science. NeuroQuest has licensed the intellectual property covering this technology from Yeda (the Technology Transfer Company of the Weizmann Institute of Science) and holds an exclusive global license for its development and commercialization.
NeuroQuest has established a US subsidiary and clinical development center in Charleston, South Carolina with the assistance and financial support of the South Carolina Research Authority (SCRA). They are working with Vikor Scientific, a CLIA-certified lab, to provide the data required for FDA approval, and with Pentara Corporation for data analysis.
Funding history · 2 rounds · $1.8M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NeuroQuest's primary product?
- NeuroQuest's primary product is NeuroScreen™, a blood-based diagnostic test for Alzheimer's disease (AD).
- What is the scientific basis for NeuroQuest's technology?
- NeuroQuest's technology is based on the specific response of the immune system to amyloid-beta accumulation, stemming from research by Professor Michal Schwartz of the Weizmann Institute of Science.
- From whom did NeuroQuest license its core technology?
- NeuroQuest licensed the intellectual property for its technology from Yeda, the Technology Transfer Company of the Weizmann Institute of Science, holding an exclusive global license.
- Where has NeuroQuest established a US presence?
- NeuroQuest has established a US subsidiary and clinical development center in Charleston, South Carolina, with assistance and financial support from the South Carolina Research Authority (SCRA).
- Which organizations are collaborating with NeuroQuest for FDA approval data and data analysis?
- NeuroQuest is working with Vikor Scientific, a CLIA-certified lab, for data required for FDA approval, and with Pentara Corporation for data analysis.
- When did NeuroQuest raise its Seed round and who were the investors?
- In December 2012, NeuroQuest raised a Seed round with investments from The Trendlines Group and The InterTech Group.
- When did NeuroQuest secure its Series A funding and from whom?
- In May 2024, NeuroQuest secured Series A funding from the South Carolina Research Authority.
- What was the key finding from a collaborative study by NeuroQuest and AIBL in November 2022?
- In November 2022, a collaborative study by NeuroQuest and AIBL showed that specific biomarkers for Alzheimer's could lead to a blood-based screening tool.
- What was the focus of a publication by NeuroQuest in November 2022?
- In November 2022, NeuroQuest published research on leukocyte surface biomarkers implicating deficits of innate immunity in sporadic Alzheimer's disease.